Background: Testicular cancer is the most common type of cancer among Norwegian 15 to 40-year-old men. The incidence has doubled in Norway and Denmark during the last 50 years and is currently the highest in the world.
Material and methods: The review article is based on relevant publications, own research and clinical experience.
Results and interpretation: Post-orchiectomy treatment is only offered at university hospitals. Cisplatin-based chemotherapy (introduced in Norway in the early 1980s) has resulted in a remarkably improved survival for patients with advanced testicular cancer. Most patients are cured (> 80%), also those with metastases. Cancer-related survival approaches 95%. Treatment-induced side effects and efforts to reduce these have been an issue of increasing importance during recent years.